Akademik Veri Yönetim Sistemi
NIGERIAN JOURNAL OF CLINICAL PRACTICE, cilt.27, sa.12, ss.1405-1409, 2024 (SCI-Expanded)
Objectives:Allo-Hematopoietic Stem Cell Transplantation (HSCT) offers a curative option for relapsed and refractory multiple myeloma in younger aged and fit patients with high-risk cytogenetic properties.Material and Methods:This study retrospectively enrolled the medical data of 30 patients who had undergone allogeneic stem cell transplantation at the Gazi University Adult Stem Cell Transplant Unit between 2005 and 2020.Results:Before allo-SCT, 6 (20.0%) patients were in complete remission; 8 (26.6%) had a partial response; 14 (46.6%) had progressive disease, and 2 (6.6%) had stable disease. Overall survival (OS) at 1, 2, 3, and 5 years post-transplant were 45%, 36.3%, 31.7%, and 22.7%, respectively; transplant-related mortality (TRM) was 25.0% at 100 days. While the 5-year OS was 11.7% in the group with less than PR according to the pre-transplant disease status, it was found to be statistically significant as 45.8% in the group with CR or PR (P = 0.001). TRM was significantly higher in patients with less than PR compared has CR or PR at pre-transplantation (100% vs. 43.7% P = 0.01). Like these findings, PFS was shorter in patients with less than PR compared has CR or PR at pre-transplantation (6.2 vs. 77.1 months, P = 0.01).Conclusions:We found longer OS and PFS in patients with a complete response before allo-SCT. This shows that the depth of response before allogeneic stem cell transplantation is effective on 100-day TRM in multiple myeloma patients. Allo-HSCT may be a therapeutic option in MM patients who relapse/refractory after auto-SCT, particularly after achieving the least partial response.